Stopping Statins at 75 Didn't Increase Deaths in Healthy Adults

Most physicians were taught that statins are forever. Start them when the LDL climbs, the guidelines say, and keep prescribing them until the patient can't swallow a pill. A randomized non-inferiority trial published in The Lancet Healthy Longevity[1] on August 11, 2026 complicates that story — at least for a specific, healthy older population. Stopping the drugs at age 75 in patients who had never had a heart attack or stroke did not result in more deaths or more major cardiovascular events three years later.

The trial enrolled 1,160 French adults through general practitioners' offices. The average age was 80. All participants had been prescribed statins for at least one year as a preventive measure — meaning they had high LDL cholesterol but no history of heart attack, stroke, or other atherosclerotic disease. Most had been on statins for five years or more. Investigators randomly assigned half to stop and half to continue, then followed everyone for three years[1].

The LDL numbers told a blunt story almost immediately. Within three months, the discontinuation group's LDL jumped 50% — from an average of 115 mg/dL to 171 mg/dL. The group staying on statins held flat. Cholesterol, it turns out, comes back quickly. But by the end of the study, that biochemical difference had not translated into a difference in hard outcomes. Deaths occurred in 7.2% of the discontinuation group (35 of 484) versus 7.9% of the continuation group (48 of 604) — a difference that fell well within the bounds of non-inferiority[1]. There was no meaningful gap in heart attacks, strokes, or other major cardiovascular events. Quality of life — measured both physically (can you climb stairs? are you in pain?) and mentally (are you sad? is your social life limited?) — stayed identical across both groups.

The authors were expecting, and hoping, that stopping the daily pill would translate into a better quality of life. It didn't — possibly because the patients most bothered by statins had already quit on their own before the trial began, leaving a group largely unbothered by the medication in both arms. That self-selection effect may also explain why the results look so benign: this is a population that was managing well on statins, not struggling with side effects or medication burden.

Clinical Context

The evidence base for statins in older adults has always been thinner than the prescribing rates would suggest. Landmark trials like 4S[2], HPS[3], and JUPITER[4] enrolled populations skewed toward middle age; the benefit data for patients over 75, especially those without established cardiovascular disease, has been extrapolated rather than directly measured. What data exist are mixed: a 2021 Danish cohort study and a concurrent Italian cohort study each found roughly 30% higher risks of fatal and nonfatal cardiovascular events when statins were stopped in patients 65 to 75 and older. But those studies were not randomized. The patients who discontinued statins in those cohorts may have done so because they were sicker, more frail, or facing competing mortality risks — not because stopping the drug was inherently harmful. The French trial, by randomly assigning patients, removes that bias.

There is also a physiological reason to think the calculus changes with age. The link between LDL cholesterol and cardiovascular events weakens progressively as patients grow older. Atherosclerotic plaques take decades to accumulate; by age 75, the plaques are already there. Lowering LDL further may matter far less for event prevention than it did at 50. Fabrice Bonnet, professor of internal medicine at Bordeaux University Hospital and a study co-author, put it plainly: "Cholesterol is no longer a high risk for elderly people. At 50 years old, it is, but at 75, it is no longer — when you have diabetes and hypertension."

Limitations

This was a French trial, and France is not the United States. France has universal primary care, the lowest cardiovascular mortality among high-income countries, and higher life expectancy than the US — all of which means the participants were healthier at baseline than most Americans the same age. The follow-up was three years, and three years may not be long enough to observe event-rate differences in a group where plaques accumulate over decades. The study only enrolled primary-prevention patients — people who had never had a heart attack or stroke. It says nothing about the 50-year-old on a statin after an MI, or the 78-year-old with a prior coronary stent. Romit Bhattacharya, a preventive cardiologist at Mass General Brigham, was direct: "For the majority of American patients over the age of 75, this trial will not change anything." The signal here is about shared decision-making flexibility for a narrow, carefully selected population — not a license for broad deprescribing.